Search Results
22 protocol(s) meet the specified criteria
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

Phase IB/II Study to Assess the Safety, Tolerability, and Efficacy of BGB-290 in Combination with Radiation Therapy and/or Temozolomide in Subjects with First-Line or Recurrent/Refractory Glioblastoma

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

108893Not Open *
Open-Label, Randomized, Controlled, Phase III Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Phase I and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases

Multi-Tracer PET Assessment of Primary Brain Tumors

Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-Fluoromisonidazole, [18F]fluoro-2-deoxy-D-glucose (FDG) and [15O]water (H215O)

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

87014Not Open *
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Randomized, Phase III, Open-Label Study of Nivolumab versus Temozolomide each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma

Randomized, Phase II, Single-Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

Phase II, Multicenter, Open-Label Study of a Conditionally Replicative Adenovirus (DNX-2401) with Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE)

Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy

Phase II Study of Abemaciclib in Recurrent Glioblastoma

INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)

Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients with Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study

Proof-of-Concept, Pilot Study of Pembrolizumab in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype